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Abstract
Objectives—Antineutrophil cytoplasmic antibody small-vessel vasculitis (ANCA-SVV) is an
autoimmune systemic process increasingly recognised since the advent of antibody testing for the
disease. Prompt diagnosis and institution of immunosuppressive therapy has been shown to
improve patient outcome. The goal of this study was to better understand how patients navigate
the health care system from symptom presentation to biopsy diagnosis, and to study the effects of
prompt versus delayed diagnosis.
Methods—Disease symptoms and number of physicians seen prior to renal biopsy were assessed
for 127 ANCA-SVV patients. Direct, delayed, and quest pathways to diagnosis and treatment of
vasculitis were defined for both patients and providers. Kruskal-Wallis and Fisher exact tests were
used to evaluate continual measures and compare categorical variables across pathways.
Results—Among patients who sought direct care, physician delay in referral to a nephrologist
was common (49/127, 71%, p=0.0023). Patients who delayed seeking care also experienced a
delayed diagnosis 57% of the time (p=0.0023). Patients presenting with prodromal flu or upper
respiratory involvement were more likely to have a delay/quest patient pathway (56% and 55%,
respectively) than a direct patient pathway (44%, p=0.033 and 45%, p=0.019, respectively). There
was a trend for patients with more severe loss of renal function to have a more direct referral to a
nephrologist.
Conclusion—Delay in diagnosis of ANCA SVV may be due to lack of or non-specific
symptoms, especially in patients who present with non-renal manifestations of disease. Better
algorithms are needed to identify extra-renal manifestations, expedite diagnosis and improve
patient outcomes.
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Small-vessel inflammation and necrosis associated with antineutrophil cytoplasmic
antibodies (ANCA) leads to significant morbidity and mortality in affected patients.
Approximately 90% of patients with pauci-immune small-vessel vasculitis have circulating
ANCA which play an active role in its pathogenesis (1, 2). ANCA small-vessel vasculitis
(ANCA-SVV) can present with a constellation of symptoms and the clinical course can be
progressive and potentially fatal, primarily due to pulmonary haemorrhage (3-5).
Immunosuppressive therapy leads to remission of ANCA-SVV in 80% of patients, but some
may suffer substantial sequelae from irreversible organ injury due to vasculitis or adverse
effects of treatment (5-7). Conversely, a rapid initiation of therapy significantly improves
morbidity and mortality from vasculitis (6-10).
ANCA-SVV may present with protean manifestations, often affecting more than one organ,
making a definitive and timely diagnosis difficult. Pauci-imune necrotising and crescentic
glomerulonephritis affects 75 to 90% of patients with ANCA-SVV and may present in a
spectrum ranging from asymptomatic microscopic haematuria to rapidly deteriorating renal
function (11). Unless there is overt haematuria (which is uncommon), the disease usually
goes unnoticed by patients until there is severe chronic damage. More clinically overt
disease manifestations involve the lungs, upper respiratory tract, peripheral nerves, skin and
joints (12-16). Commonly associated constitutional symptoms such as weight loss, fatigue,
migratory joint pains and flu-like illness broaden the differential diagnosis (17). Prompt
institution of immunosuppressive therapy with cyclophosphamide and corticosteroids
improves long term renal outcome and patient survival (18, 19). Approximately 20% of
patients are resistant to treatment and progress to end stage kidney disease (ESKD) within
two months (8, 20). Treatment resistance is primarily associated with a presentation of
severely depressed renal function and the presence of severe glomerular and interstitial
scarring on renal biopsy.
The rapidity with which a patient presents to medical attention and proper treatment is
commenced have a critical impact on ultimate organ damage and overall patient outcome.
Understanding how patients come to medical attention and how the diagnosis is established
once in the medical system are critical in terms of minimising chronic damage, especially
the irreversible loss of kidney function. The purpose of this study was to evaluate pathways
from onset of symptoms to diagnosis of ANCA-SVV, considering disease awareness and
barriers to care by both patients and physicians. We hypothesised that the presence of more
severe and clinically apparent symptoms (e.g. haemoptysis) lead patients to seek medical
attention more promptly, and result in a quicker diagnosis compared to more subtle or
indolent disease manifestations (e.g. asymptomatic microscopic haematuria). We also
postulated that a delay in diagnosis would result in more frequent progression to ESKD.
Materials and methods
Study participants
Data was collected through telephone interviews as part of a population-based case-control
study to evaluate the association of environmental factors, drugs and co-existing diseases
with the onset of ANCA-SVV (21, 22). Details of the case-control study have previously
been described (21), with only information on case participants used for this analysis. In
brief, eligible patients were between 18 and 84 years old and had a diagnosis of ANCA-
SVV with renal biopsy proof of pauci-immune necrotising glomerulonephritis.
Nephropathologists throughout the region identified patients with an initial renal biopsy
between October 1997 and October 2003. This allowed comprehensive ascertainment of
patients with newly diagnosed ANCA-SVV with glomerulonephritis, although an unknown
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number may progress to ESKD without undergoing a renal biopsy. ANCA positivity,
determined by indirect immunofluorescence microscopy and/or antigen-specific ELISA, was
classified as either cytoplasmic and/or proteinase 3-ANCA (referred to as C/PR3-ANCA) or
perinuclear and/or myeloperoxidase-ANCA (referred to as P/MPO-ANCA) (23-25). P-
ANCA alone required a negative antinuclear antibody test.
Of 498 potential cases identified, 214 cases met the entry criteria and 128 (60%) completed
the full interview and had complete information on their diagnosis history. Patients who
participated in the telephone interview were similar to the overall population of patients
identified during the study period with respect to age, sex and race (21).
Survey instrument
Trained interviewers from Battelle Centers for Public Health Research and Evaluation
conducted the structured, computer-assisted telephone interviews. All study materials were
approved by the Institutional Review Board at the University of North Carolina at Chapel
Hill.
Information on a variety of topics was collected during the interview, including symptoms at
disease presentation, occupational history, smoking history, and medical and medication
history. Participants were asked to identify the time of onset and the type of first symptoms
of vasculitis or kidney disease. Patients were also asked the number and type of physicians
they had seen, whether or not they were hospitalised for their symptoms and/or whether they
were diagnosed with vasculitis at the time of their hospitalisation. A list of presenting
symptoms typically associated with vasculitis or kidney disease was used for the survey,
followed by an open-ended question about any symptoms not listed. These symptoms were
then categorised into groups: prodromal syndrome (flu and/or night sweats), weight loss,
joints, lung (coughing up blood, trouble breathing), upper respiratory (recurrent or persistent
sinus problems/nose bleeds, ear infections), eyes (red/painful eyes), skin, neurological, and
renal (haematuria).
Conceptualisation and operationalisation of diagnostic pathways
Definitions of pathways to diagnosis were adapted from those used in a study of the journey
to diagnosis for paediatric patients with chronic illness (26). Responses were coded into
pathway categories defined as Direct, Delay, and Quest, separately for the patient and their
physician(s). In general, pathway categories were defined by the time it took for the patient
to seek care and/or get referred to a nephrologist by their primary doctor, number of doctors
seen prior to their renal biopsy, and symptoms that were missed or mis-identified (Fig. 1).
A detailed log for each patient was constructed from the telephone interview responses by a
social worker familiar with symptoms and patient diagnosis issues related to ANCA-SVV
(CJP). The detailed log documented the date of first symptoms, date of first renal biopsy
diagnosis of ANCA glomerulonephritis, a list of symptoms at or before the renal biopsy,
which symptoms prompted the patient to seek medical attention or required hospitalisation,
number and types of doctors seen, and information on if and when the patient reached
ESKD. These logs were then used to apply a “patient pathway category” and a “MD
pathway category”. A written explanation for categorisation was included for each patient
for further clarification. A second reviewer (SLH) examined each patient log and pathway
category. Discrepancies in pathway categories between the two reviewers were discussed
until an agreement was reached for a final pathway categorisation for the patient and the
physician. Patient and physician categories were also synthesised to create an “overall”
pathway category. The worse (longest) pathway of the two was selected as the overall
category.
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Estimated glomerular filtration rate (eGFR) was used to determine the level of kidney
function and was calculated using the abbreviated Modification in Diet and Renal Disease
(MDRD) Study formula based on serum creatinine, age, sex and race (27, 28). Acute
dialysis was defined as a period of dialysis lasting three months or less, followed by
recovery and discontinuation of dialysis. ESKD was defined as the need for chronic dialysis
or a kidney transplant.
Statistical methods
Descriptive statistics in this study are presented as number with percent, mean with standard
deviation, or median with interquartile range. Kruskal-Wallis tests were used to evaluate for
differences in continuous measures between the three pathway categories - Direct, Delay,
and Quest. Fisher’s exact tests were used to compare categorical variables across pathway
and disease categories. Exact p-values are reported, with an alpha level of 0.05 considered




The 128 patients included in the study had a mean age of 62 (± 14) years and 84% were
Caucasian. Forty-four percent of patients were MPO-ANCA positive, 34% PR3-ANCA
positive and 22% had a positive ANCA test by IIFM, but no information on antigen
specificity. Details on antigen specificity as well as on diagnosis category was missing in 25
patients. The characteristics of this cohort were representative of the entire ANCA registry
and of ANCA SVV in the general population (3, 8, 29, 30). Chart review was available in
103 patients (80%), among whom 22% were categorised as having granulomatosis with
polyangiitis (GPA, formerly Wegeners Granulomatosis (30)), 44% with microscopic
polyangiitis (MPA) and 34% with ANCA glomerulonephritis without systemic
manifestations of the disease (renal limited).
Individual patient and physician pathways
With respect to patient pathways to diagnosis (Fig. 2), 54% of patients sought direct care
(n=69), 26% (n=33) had a delayed course due to patient-related factors and 20% (n=26) had
a quest course. Patients with skin involvement (n=31) were more likely to have a direct
(74%) than a delay/quest patient pathway (26%, p=0.015); whereas patients with prodromal
flu-like (n=64) or upper respiratory tract symptoms (n=76) were more likely than expected
to have a delay/quest patient pathway (56% and 55%, respectively) than a direct patient
pathway (44%, p=0.033 and 45%, p=0.019, respectively). Demographic characteristics,
health insurance or symptoms associated with other organ-system involvement did not
influence the patient pathway.
With respect to physician pathways (Fig. 2), direct referrals to nephrology occurred in only
26% of cases (n=33) whereas it was delayed in 71% (n=91), and 3% (n=4) had a quest
course (p=0.0001). There was a trend for upper respiratory involvement to also lead to more
frequent delay/quest physician pathway (80%) than a direct physician pathway (20%,
p=0.07). Patients who received a direct referral to nephrology had a lower eGFR (median
14.5 ml/min/1.73m2, IQR 11.1) than those who had a delay/quest physician pathway
(median eGFR 20.6 ml/min/1.73m2, IQR 25.4; p=0.028). Similarly, the need for acute
dialysis was associated with a higher than expected direct physician pathway (50%) than
delay/quest physician pathway (50%, p=0.08). Demographics, health insurance and other
organ system involvement did not influence the physician pathway.
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Of the patients who sought direct care, 28% (n=19) received direct referral from the primary
care physician to a nephrologist, representing the most expeditious combined pathway.
Seventy-two percent of patients who sought direct care received a delayed referral to a
nephrologist (n=49 delayed and n=1 quest by the physician). For patients in this group
disease-related symptoms placed them on a direct pathway toward treatment but provider
delays lead to delayed diagnosis. The cause(s) of this delay are not apparent from our
analysis. There were no statistical differences in patient demographics, health insurance, or
organ involvement comparing patient-direct to physican-direct pathway, or comparing
patient-delay/quest to physician- delay/quest pathway. Among patients who were in the
delay (n=33) and quest (n=26) categories by patient related factors, 24% received a direct
referral to a nephrologist from the primary care physician. This group of patients was given
the most expeditious diagnosis by the medical community despite patient related delays.
Seventy-six percent of patients had a delay from patient related factors and were further
delayed by the provider (p=0.62).
Combined/overall pathways
The combined/overall pathway categorisation resulted in a majority of participants (79/128
or 62%) with a delayed diagnosis, either by the physician or the patient’s not seeking care.
Only fifteen percent of patients (19/127) were categorised as having a direct pathway and
23% (29/127) fell into the quest category. There were no significant differences between
pathway categories by age, race, sex, insurance status, or education (Table I). There was a
trend of increasing predominance of PR3-ANCA positivity along the continuum of the
direct, delay and quest categories respectively (27%, 41% and 56%, respectively, p=0.06)
(Table I). Disease diagnosis (GPA, MPA, Renal Limited) was not different between groups
(Table I).
Patients with upper respiratory symptoms represented 60% of those in the delay category
and 77% in the quest category in contrast with 32% in the direct category; p=0.0078 (Table
II). Lung involvement was also more common among those categorised in the quest
pathway compared to those categorised as direct or delay, (57% vs. 26% and 32%,
respectively, p=0.04). There was less frequent history of joint symptoms and a trend for less
prodromal flu-like symptoms among those in the direct category compared to those in the
delay and quest categories (Table II).
The need for acute dialysis at or before renal biopsy, eGFR, and progression to ESKD or
death were not statistically different across overall pathway groups. Patients diagnosed with
renal limited disease had a lower median eGFR at diagnosis compared to those with extra-
renal involvement (15.82 vs. 27.9 ml/min/1.73m2; p=0.0084), with 50% versus 27%,
respectively, having an eGFR ≤15 ml/min/1.73m2 (p=0.038).
Discussion
It has previously been suggested that significant delays in diagnosis of ANCA vasculitis are
common and have a negative impact on the long term outcomes of patients. Our study
documents and confirms these frequent delays in diagnosis. These delays are attributable to
patient delays in seeking care, as well as delays by their treating physicians in establishing
the diagnosis. Our study was not designed to critically establish the causes of patient delays.
These are conceivably attributable to a number of possible clinical, socioeconomic or
personal causes.
The specific manifestation of symptoms and the concern a patient feels about any given
symptoms may help to explain whether a patient presents to a physician expeditiously or
with a delay. The presence of non-specific systemic symptoms alone, such as flu-like or
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upper-respiratory tract symptoms, appears to be associated with a delay in seeking medical
attention. Interestingly, there is a strong association between skin manifestations and a direct
patient pathway to care. Unfortunately, our data were not detailed enough to evaluate the
kind of skin findings that prompted such a strong patient response.
Although not definitive, our results provide an interesting window into patients’
interpretation and response to their symptoms, and may help improve patient education in
the future. Previous studies suggested that disease onset with systemic features lead to
patients seeking more prompt medical care (32-36). Our study documents delays in
diagnosis even after patients have sought medical attention. In this setting, we hypothesised
that the presence of overt extra-renal manifestation of disease would lead to a more rapid
diagnosis because the glomerulonephritis associated with ANCA-SVV may be associated
with relatively few symptoms until far advanced. Our data however refute this hypothesis. In
this study, the presence of extra-renal manifestations were all more frequent than expected
in the MD delay/quest group than the direct group, although these differences reached
statistical significance only for musculoskeletal symptoms. Instead of acting as clues for the
presence of systemic vasculitis, the extra-renal manisfestations appear to lead the treating
physician to focus on these, and their common causes (e.g. pneumonia, sinusitis). In such
situations, the diagnosis of systemic vasculitis is typically entertained only after the patient
fails to improve, or presents with recurrent signs and symptoms despite common therapy. In
the absence of multi-organ involvement, and when symptoms are non-specific, systemic
vasculitis is typically not entertained in the differential diagnosis.
Research done with primary care physicians found that diagnosis and disease management
are negatively impacted by the lack of availability of diagnostic tests, symptoms not
typically associated with a certain disease, and physician reluctance to committing to an
intensive course of action (37, 38). Moreover co-morbidities related to age and the increased
risk of toxicities from immunosuppressive treatments might negatively influence the workup
for vasculitis. This phenomenon has also been recognised in other autoimmune diseases with
a wide spectrum of clinical manifestations such as systemic lupus erythematosus and
rheumatoid arthritis (39, 40). Our findings imply that more education may be needed to
provide physicians with tools and algorithms to raise the suspicion for and more
expeditiously diagnose systemic vasculitis. Whether a particular constellation of findings
can point the primary care physician towards a diagnosis of vasculitis requires further
research.
It is intriguing that patients in the delay/quest MD pathway had a statistically significantly
higher eGFR than those in the direct MD pathway (median 20.6 ml/min/1.73m2, IQR 25.4;
vs. 14.5 ml/min/1.73m2, IQR 11.1; p=0.03), although the median eGFR was low in both
groups. These results suggest that patients are referred to a nephrologist only when very
severe renal failure is detected, and the need for renal replacement therapy is imminent.
Such delays are expected to be associated with a decreased likelihood of response to therapy
from the renal point of view, as the GFR at the time of treatment initiation has been
demonstrated to be a strong predictor of outcome (3).
There are a number of limitations to this study. Many confounding variables were not
explored in this paper that may affect the pathways to diagnosis, including access to health
care, educational level, and type of specialist seen, due to the nature of the survey questions
asked. There was also the risk of recall bias, as this was a telephone interview asking for
past medical history solely from a patient’s perspective. However, all patients were
interviewed within 5 years of their diagnosis thus limiting recall of events in the distant past.
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In conclusion, ANCA-SVV is a multi-systemic disease with a variety of presenting
symptoms that can baffle both the affected person and the attending physician. Better
algorithms are needed to help physicians consider a vasculitic or autoimmune process with
or without renal involvement in their differential diagnosis. Further study is needed, using
patient and provider input, as well as structured medical chart review, to better understand
and expedite a patient’s pathway to ANCA-SVV diagnosis.
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*For overall/combined pathway, the worst (longest) pathway was chosen of the two.
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Schematic representation of patient pathways (n=128).
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Table I
Demographic and disease characteristics by overall pathway category.









Mean age (years) 63.8 ± 11.8 62.2 ± 14.4 58.0 ± 14.7 0.27
Sex: 0.47
  Male 11 (58%) 50 (63%) 15 (50%)
Race 0.83
  White 17 (89%) 65 (82%) 26 (87%)
High school education or less 11 (58%) 38 (48%) 16 (53%) 0.72
Any form of health insurance 17 (89%) 65 (82%) 25 (83%) 0.89
Diagnosis category
††
 MPA* 5 (36%) 34 (52%) 8 (33%) 0.46
 Renal limited 6 (43%) 18 (28%) 9 (38%)
 GPA 3 (21%) 13 (20%) 7 (29%)
Measures used to define pathway categories:
Number of Physicians seen
 (median months and IQR
¶
)
1 (0) 1 (1) 4 (2) <0.0001
Hospitalisation without a diagnosis
 of vasculitis
4 (21%) 15 (19%) 14 (47%) 0.0165
Time from first symptom to renal
 biopsy (median months and IQR¶)
1.0 (2) 4.0 (10) 8.5 (50) <0.0001
†
Comparison of measures across the 3 overall pathway groups.
††
Disease diagnosis only available for n=103 patients.
*
2 Churg-Strauss were included as having MPA.
¶
IQR: Inter-quartile range.
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Table II
Telephone survey and clinical results by overall pathway category.
Median (IQR)









Specialist 4 (21%) 27 (34%) 18 (60%)
Usual MD 15 (79%) 52 (66%) 12 (40%)
Onset symptoms:
  Prodromal flu 5 (26%) 41 (52%) 18 (60%) 0.0624
  Lung 5 (26%) 25 (32%) 17 (57%) 0.04
  Upper respiratory 6 (32%) 47 (60%) 23 (77%) 0.0078
  Joints 4 (21%) 41 (52%) 18 (60%) 0.0204
  Skin 5 (26%) 22 (28%) 4 (13%) 0.25
  Brown urine 4 (21%) 21 (27%) 12 (40%) 0.29
eGFR; median (IQR) n=17 n=71 n=28 0.13
 (Missing12) 13.4 (11.0) 20.0 (26.3) 16.6 (24.9)
Acute dialysis* 3 (16%) 7 (9%) 2 (7%) 0.56
ESKD 6 (32%) 20 (25%) 10 (33%) 0.64
Time to ESKD n=6 n=18 n=10 0.53
 (median months and IQR
¶
) 12.7 (29.5) 1.1 (8.0) 4.0 (19)
Death 4 (21%) 16 (20%) 2 (7%) 0.21
Time to death n=4 n=16 n=2 0.10
 (median months and IQR
¶




Comparison of measures across the 3 overall pathway groups.
*
Acute dialysis: patients who presented with need for renal replacement therapy but recovered renal function with treatment and did not require
permanent dialysis.
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